These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
610 related articles for article (PubMed ID: 21778212)
1. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871 [TBL] [Abstract][Full Text] [Related]
3. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790 [TBL] [Abstract][Full Text] [Related]
4. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Pallante P; Visone R; Croce CM; Fusco A Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715 [TBL] [Abstract][Full Text] [Related]
5. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508 [TBL] [Abstract][Full Text] [Related]
6. Cytological features of well-differentiated tumors of uncertain malignant potential: Indeterminate cytology and WDT-UMP. Nishigami K; Liu Z; Taniguchi E; Koike E; Ozaki T; Mori I; Kakudo K Endocr J; 2012; 59(6):483-7. PubMed ID: 22484994 [TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential. Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744 [TBL] [Abstract][Full Text] [Related]
9. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058 [TBL] [Abstract][Full Text] [Related]
10. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features. Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472 [TBL] [Abstract][Full Text] [Related]
12. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505 [TBL] [Abstract][Full Text] [Related]
13. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574 [TBL] [Abstract][Full Text] [Related]
16. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features. Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. Rossing M; Borup R; Henao R; Winther O; Vikesaa J; Niazi O; Godballe C; Krogdahl A; Glud M; Hjort-Sørensen C; Kiss K; Bennedbæk FN; Nielsen FC J Mol Endocrinol; 2012 Feb; 48(1):11-23. PubMed ID: 22049245 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043 [TBL] [Abstract][Full Text] [Related]
19. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma. Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622 [TBL] [Abstract][Full Text] [Related]
20. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Liu Z; Zhou G; Nakamura M; Koike E; Li Y; Ozaki T; Mori I; Taniguchi E; Kakudo K Cancer Sci; 2011 Jan; 102(1):288-94. PubMed ID: 21070478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]